Login to Your Account

Financings Roundup

Banking on Fostamatinib, Rigel Seeks to Raise $130M

By Catherine Shaffer
Staff Writer

Thursday, October 4, 2012

A public offering worth $130 million will extend Rigel Pharmaceuticals Inc.'s cash runway through potential approval of its lead product, fostamatinib.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription